Terms: = Leukemia AND SMO, Q99835, 6608, ENSG00000128602, SMOH, Gx AND Treatment
38 results:
1. treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. Ivosidenib in acute myeloid leukemia.
Bruzzese A; Labanca C; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(18):2093-2100. PubMed ID: 37874005
[TBL] [Abstract] [Full Text] [Related]
3. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract] [Full Text] [Related]
4. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo.
Wu H; Zhang L; Chen B; Ou B; Xu J; Tian N; Yang D; Ai Y; Chen Q; Quan D; Zhang T; Lv L; Tian Y; Zhang J; Wu S
Bioorg Chem; 2023 Jun; 135():106488. PubMed ID: 36989734
[TBL] [Abstract] [Full Text] [Related]
5. Construction of a target MSNs drugcarrier loaded with siRNA
Zhang Y; Cai R; Li H; Duan Y; Zhang Y; Jing W; Lv S; Chu X; Cao Z; Yang L; Ming L
Drug Deliv Transl Res; 2022 Oct; 12(10):2463-2473. PubMed ID: 35113326
[TBL] [Abstract] [Full Text] [Related]
6. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
[TBL] [Abstract] [Full Text] [Related]
7. Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models.
Kim YJ; Koh EM; Song CH; Byun MS; Choi YR; Jeon EJ; Hwang K; Kim SK; Yang SI; Jung KJ
Sci Rep; 2021 Jun; 11(1):12004. PubMed ID: 34099775
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract] [Full Text] [Related]
9. [NCTD Retards AML HL60 Cell Proliferation via Targeting Hedgehog/SOX2 axis].
Fu MY; Chen WW; Gao N; Li S; DU J; Yu WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):32-37. PubMed ID: 33554793
[TBL] [Abstract] [Full Text] [Related]
10. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the treatment of Acute Myeloid leukemia.
Jamieson C; Martinelli G; Papayannidis C; Cortes JE
Blood Cancer Discov; 2020 Sep; 1(2):134-145. PubMed ID: 34661144
[TBL] [Abstract] [Full Text] [Related]
11. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
Thomas X; Heiblig M
Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
[No Abstract] [Full Text] [Related]
12. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
Chahal KK; Li J; Kufareva I; Parle M; Durden DL; Wechsler-Reya RJ; Chen CC; Abagyan R
PLoS One; 2019; 14(9):e0214901. PubMed ID: 31539380
[TBL] [Abstract] [Full Text] [Related]
13. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
Katoh M
Clin Sci (Lond); 2019 Apr; 133(8):953-970. PubMed ID: 31036756
[TBL] [Abstract] [Full Text] [Related]
14. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid leukemia treatment.
Terao T; Minami Y
Cells; 2019 Apr; 8(4):. PubMed ID: 30987263
[TBL] [Abstract] [Full Text] [Related]
15. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract] [Full Text] [Related]
16. A novel hedgehog inhibitor for the treatment of hematological malignancies.
Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
[TBL] [Abstract] [Full Text] [Related]
17. [Current diagnosis and treatment for acute myeloid leukemia].
Kobayashi Y
Rinsho Ketsueki; 2017; 58(4):364-372. PubMed ID: 28484168
[TBL] [Abstract] [Full Text] [Related]
18. NANOG Expression as a Responsive Biomarker during treatment with Hedgehog Signal Inhibitor in Acute Myeloid leukemia.
Kakiuchi S; Minami Y; Miyata Y; Mizutani Y; Goto H; Kawamoto S; Yakushijin K; Kurata K; Matsuoka H; Minami H
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245563
[TBL] [Abstract] [Full Text] [Related]
19. Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to smo and GLI1 inhibitors.
Dagklis A; Demeyer S; De Bie J; Radaelli E; Pauwels D; Degryse S; Gielen O; Vicente C; Vandepoel R; Geerdens E; Uyttebroeck A; Boeckx N; de Bock CE; Cools J
Blood; 2016 Dec; 128(23):2642-2654. PubMed ID: 27694322
[TBL] [Abstract] [Full Text] [Related]
20. Primary cilia are present on human blood and bone marrow cells and mediate Hedgehog signaling.
Singh M; Chaudhry P; Merchant AA
Exp Hematol; 2016 Dec; 44(12):1181-1187.e2. PubMed ID: 27612547
[TBL] [Abstract] [Full Text] [Related]
[Next]
